Biocon EPS estimates cut by 38% by Nuvama who sees challenges for Sun Pharma, Cipla

Nuvama wrote in its note that the valuation premium of the Pharma index is holding up despite a decline of nearly 8% since October and a cut to its financial year 2025 and 2026 EPS estimates by low single digits.